|
0
|
|
Efficacy and Safety of Obeldesivir in High-Risk Nonhospitalized Patients With COVID-19 (BIRCH): A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study.
(academic.oup.com)
|
Streinu-Cercel A
…
Gonzalez Del Castillo JM
Clinical Infectious Diseases
2026-02-09
|
#covid-19
#clinical trial
#antiviral
#nucleoside
|
|
0
|
|
Retreatment With Nirmatrelvir/Ritonavir Following Return of COVID-19 Symptoms and SARS-CoV-2 Positivity.
(academic.oup.com)
|
Zhang W
…
Hammond J
Clinical Infectious Diseases
2026-02-09
|
#covid-19
#clinical trial
#antiviral
#viral rebound
|
|
0
|
|
Win Ratio Aligns With and Enhances Interpretation of REPRIEVE's Primary Findings.
(academic.oup.com)
|
Davies Smith E
…
Ribaudo HJ
Clinical Infectious Diseases
2026-02-09
|
#clinical trial
#hiv
#cardiovascular
#statins
|
|
0
|
|
Phase 2 Trial of Long-Acting Cabotegravir and VRC07-523LS for Viral Suppression in Adults With HIV-1: ACTG A5357.
(academic.oup.com)
|
Taiwo BO
…
Tebas P
Clinical Infectious Diseases
2026-02-09
|
#clinical trial
#immunotherapy
#hiv
#viralsuppression
|